Sleep in thyrotoxicosis

Sridhar, G. R.; Putcha, Venkata; Lakshmi, Gumpeny

doi:10.4103/2230-8210.77578

Cited by 22 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are few reports that specifically address sleep problem related to thyrotoxicosis. Sridhar et al performed a retrospective review of medical records to assess the quality of sleep in patients with thyrotoxicosis and found that thyrotoxicosis was associated principally with difficulty falling asleep and maintaining sleep, and that these were related to hyperkinetic features (tremor, appetite change, bowel disturbances) [ 26 ]. In our study, we will analyze various indexes related to sleep prospectively according to later changes in thyroid function, which will provide valuable information on the relationship between the quality of sleep and thyroid function.…”

Section: Discussionmentioning

confidence: 99%

Clinical Feasibility of Continuously Monitored Data for Heart Rate, Physical Activity, and Sleeping by Wearable Activity Trackers in Patients with Thyrotoxicosis: Protocol for a Prospective Longitudinal Observational Study

Lee

et al. 2018

JMIR Res Protoc

View full text Add to dashboard Cite

BackgroundThyrotoxicosis is a common disease caused by an excess of thyroid hormones. The prevalence of thyrotoxicosis about 2% and 70-90% of thyrotoxicosis cases are caused by Graves' disease, an autoimmune disease, which has a high recurrence rate when treated with antithyroid drugs such as methimazole or propylthiouracil. The clinical symptoms and signs of thyrotoxicosis include palpitation, weight loss, restlessness, and difficulty sleeping. Although these clinical changes in thyrotoxicosis can be detected by currently available wearable activity trackers, there have been few trials of the clinical application of wearable devices in patients with thyrotoxicosis.ObjectiveThe aim of this study is to investigate the clinical applicability of wearable device-generated data to the management of thyrotoxicosis. We are analyzing continuously monitored data for heart rate, physical activity, and sleep in patients with thyrotoxicosis during their clinical course after treatment.MethodsThirty thyrotoxic patients and 10 control subjects were enrolled in this study at Seoul National University Bundang Hospital. Heart rate, physical activity, and sleep are being monitored using a Fitbit Charge HR or Fitbit Charge 2. Clinical data including anthropometric measures, thyroid function test, and hyperthyroidism symptom scale are recorded.ResultsStudy enrollment began in December 2016, and the intervention and follow-up phases are ongoing. The results of the data analysis are expected to be available by September 2017.ConclusionsThis study will provide a foundational feasibility trial of the clinical applications of biosignal measurements to the differential diagnosis, prediction of clinical course, early detection of recurrence, and treatment in patients with thyrotoxicosis.Trial RegistrationClinicalTrials.gov NCT03009357; https://clinicaltrials.gov/ct2/show/NCT03009357 (Archived by WebCite at http://www.webcitation.org/6wh4MWPm2)

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Feasibility of Continuously Monitored Data for Heart Rate, Physical Activity, and Sleeping by Wearable Activity Trackers in Patients with Thyrotoxicosis: Protocol for a Prospective Longitudinal Observational Study

Lee

et al. 2018

JMIR Res Protoc

View full text Add to dashboard Cite

show abstract

“…[ 26 ] Some other unusual association that has been found in relation to thyroid dysfunction is increased risk of dysglycemia – a MetS defining criterion – in TD subjects with impaired sleep disorder. [ 27 ]…”

Section: Discussionmentioning

confidence: 99%

The metabolic syndrome in thyroid disease: A report from Nigeria

Ogbera

Kuku

Dada

2012

Indian J Endocr Metab

View full text Add to dashboard Cite

Background:The objective of this study was to determine the prevalence of the metabolic syndrome and its components in people with thyroid disorders.Materials and Methods:112 subjects with a history of thyroid disorders were consecutively enrolled for the study. Clinical data were obtained by interviewing the patients and referring to their case folders and prescriptions. The subjects were categorized into three: thyrotoxic, those with hypothyroidism and those with nontoxic goiters, based on clinical parameters and or thyroid function tests. The study subjects were weighed and their anthropometric indices were documented. The laboratory parameters that were analyzed included total cholesterol, high-density and low-density cholesterol and triglyceride. Statistical analysis was performed using Student's t test, one-way analysis of variance (ANOVA) test and chi-square test.Results:The study subjects were aged between 14 and 76 years, with a mean age of 44.5 years, and the female:male ratio was 97:15. The mean age and anthropometric indices were comparable in subjects with thyrotoxicosis, hypothyroidism and euthyroidism. The overall prevalence of the metabolic syndrome was 28% and the frequency of occurrence of the metabolic syndrome in subjects with thyrotoxicosis, hypothyroidism and nontoxic goiter was 24%, 40% and 42%, respectively. The commonest occurring metabolic syndrome defining criterion was dysglycemia, while hypertension and elevated triglyceride were the least documented of the criteria.Conclusion:Metabolic syndrome occurs in 1 in every 4 persons with thyroid disorders, and as such, routine screening for this cardiovascular risk factor may be of benefit in this group of people, especially in those with hypothyroidism.

show abstract

“…Sleep disorders are common in major organ impairment as in chronic kidney or liver disease [8]. Hyperthyroidism is also an important hormonal cause of insomnia [9]. EEG detects epileptiform activity as various epileptic syndromes occur during sleep, thereby causing insomnia and affecting cognition.…”

Section: Discussionmentioning

confidence: 99%